Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SRPT

Sarepta Therapeutics Inc

Mar 09 • 04:00PM ET

17.64

+0.93 5.57 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN ALNY IONS PFE PTCT EXEL PRTA BLUE RDUS

| Held by: IJR VTI FBT XBI VB VBK VXF SPSM FXH IBB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-8.44	Insider Own	5.28%	Shs Outstand	104.96M	Perf Week	8.09%
Market Cap	1.85B	Forward P/E	12.95	EPS next Y	1.36	Insider Trans	-0.24%	Shs Float	99.44M	Perf Month	3.58%
Enterprise Value	1.95B	PEG	-	EPS next Q	1.11	Inst Own	91.48%	Short Float	22.32%	Perf Quarter	-22.70%
Income	-842.79M	P/S	0.84	EPS this Y	144.44%	Inst Trans	-0.58%	Short Ratio	8.00	Perf Half Y	-5.72%
Sales	2.20B	P/B	1.62	EPS next Y	-57.00%	ROA	-23.05%	Short Interest	22.20M	Perf YTD	-18.03%
Book/sh	10.87	P/C	1.97	EPS next 5Y	-	ROE	-63.17%	52W High	104.85 -83.18%	Perf Year	-82.88%
Cash/sh	8.95	P/FCF	-	EPS past 3/5Y	3.92% -0.05%	ROIC	-38.86%	52W Low	10.41 69.37%	Perf 3Y	-88.12%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	33.06% 32.41%	Gross Margin	59.56%	Volatility	5.53% 4.93%	Perf 5Y	-79.43%
Dividend TTM	-	EV/Sales	0.89	EPS Y/Y TTM	-438.50%	Oper. Margin	-29.92%	ATR (14)	1.06	Perf 10Y	27.18%
Dividend Ex-Date	-	Quick Ratio	1.48	Sales Y/Y TTM	15.58%	Profit Margin	-38.34%	RSI (14)	46.59	Recom	2.67
Dividend Gr. 3/5Y	- -	Current Ratio	2.32	EPS Q/Q	-344.01%	SMA20	0.08%	Beta	0.45	Target Price	20.91
Payout	0.00%	Debt/Eq	0.91	Sales Q/Q	-32.73%	SMA50	-11.29%	Rel Volume	1.34	Prev Close	16.71
Employees	835	LT Debt/Eq	0.90	Earnings	Feb 25 AMC	SMA200	-16.43%	Avg Volume	2.78M	Price	17.64
IPO	Jun 04, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	-228.27% 19.84%	Trades		Volume	3,721,990	Change	5.57%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Equal Weight	$20
Dec-09-25	Initiated	Wedbush	Outperform	$32
Nov-05-25	Upgrade	Mizuho	Neutral → Outperform	$26
Sep-22-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$50
Jul-29-25	Upgrade	Oppenheimer	Perform → Outperform	$37
Jul-29-25	Upgrade	JP Morgan	Underweight → Neutral	$24
Jul-29-25	Upgrade	Barclays	Underweight → Equal Weight	$22
Jul-29-25	Reiterated	H.C. Wainwright	Sell	$5
Jul-29-25	Initiated	Bernstein	Mkt Perform	$13
Jul-28-25	Downgrade	Barclays	Equal Weight → Underweight	$10
Jul-25-25	Downgrade	JP Morgan	Neutral → Underweight
Jul-24-25	Initiated	Citigroup	Sell	$7
Jul-23-25	Downgrade	BofA Securities	Neutral → Underperform	$10
Jul-22-25	Downgrade	Barclays	Overweight → Equal Weight	$18
Jul-21-25	Downgrade	UBS	Buy → Neutral	$12
Jul-21-25	Downgrade	Needham	Hold → Underperform
Jul-21-25	Downgrade	Mizuho	Outperform → Neutral	$14
Jul-21-25	Downgrade	Leerink Partners	Outperform → Market Perform	$10
Jul-21-25	Downgrade	Deutsche Bank	Buy → Hold	$9
Jul-18-25	Downgrade	Needham	Buy → Hold

Show Previous Ratings

Today 01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga) +5.57%
07:59AM	UniQure leads genetic medicine biotech rally after news of Prasads exit (BioPharma Dive)
07:01AM	Why Is uniQure Stock Skyrocketing Monday? (Benzinga)
Mar-06-26 05:56PM	FDA vaccine chief Vinay Prasad set to leave post next month (Bloomberg)
11:57AM	Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? (Zacks)
03:00AM	Loading…
03:00AM	Biopharmas recent string of CEO splits (Pharma Voice)
Mar-01-26 04:27AM	Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45 (Insider Monkey)
Feb-28-26 11:58AM	Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory (Insider Monkey)
09:30AM	Sarepta CEO To Jump Ship After 'Tumultuous' Year (Benzinga)
Feb-27-26 09:00AM	Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program (Business Wire)
Feb-26-26 10:29AM	Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates (Zacks) -8.01%
09:30AM	Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics (Zacks)
08:30AM	Sarepta Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
08:30AM	Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress (Business Wire)
05:52AM	Sarepta CEO To Jump Ship After 'Tumultuous' Year (Benzinga)
03:08AM	Loading…
03:08AM	Sarepta Therapeutics Q4 Earnings Call Highlights (MarketBeat)
03:00AM	Sarepta CEO Doug Ingram to retire, with company at a crossroads (BioPharma Dive)
12:05AM	Sarepta Therapeutics Inc (SRPT) Q4 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Feb-25-26 04:40PM	Sarepta Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments (Business Wire)
Feb-24-26 09:07AM	Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan (Business Wire)
08:30AM	Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference (Business Wire)
Feb-19-26 10:00AM	Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-18-26 10:00AM	Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
09:39AM	Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? (Zacks)
Feb-15-26 05:35AM	Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreichs Ataxia Update (MarketBeat)
Feb-11-26 08:30AM	Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results (Business Wire)
Feb-06-26 12:04AM	Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... (GuruFocus.com) +8.63%
Feb-05-26 08:06PM	Arrowhead Pharmaceuticals Q1 Earnings Call Highlights (MarketBeat) -13.68%
Jan-31-26 12:02AM	Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags (MarketBeat)
10:50AM	Loading…
Jan-27-26 10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
06:45AM	Sarepta eyes Elevidys sales comeback with positive Phase III data (Clinical Trials Arena)
Jan-26-26 04:17PM	Sarepta Pops On Elevidys Data; But Will It Save The Embattled Gene Therapy? (Investor's Business Daily) +7.90%
02:49PM	Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. (Barrons.com)
01:26PM	Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday? (Benzinga)
12:00PM	Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
11:56AM	Stocks to Watch Monday: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)
11:36AM	These Stocks Are Todays Movers: USA Rare Earth, CoreWeave, Micron, Intel, Newmont, IonQ, Sarepta, and More (Barrons.com)
11:23AM	Sarepta Stock Climbs 11% on Positive Three-Year Study Results for Elevidys (Barrons.com)
09:26AM	Sarepta Says Elevidys Slows Duchenne Progression After Three Years (Benzinga)
09:15AM	Is KROS' KER-065 the Next Breakthrough in DMD Space? (Zacks)
08:53AM	Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys (Barrons.com)
08:00AM	Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients (Business Wire)
06:46AM	Sarepta, battling slowing sales, claims Duchenne gene therapys impact grows with time (BioPharma Dive)
05:36AM	Stock Market Today: Dow Jones, S&P 500 Futures Slip As Investors Brace For Mega-Cap Earnings-Brand Engagement, Nucor In Focus (Benzinga)
Jan-23-26 04:05PM	Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy (Business Wire)
Jan-21-26 10:50PM	2 Beaten-Down Stocks That Could Sink Even More in 2026 (Motley Fool)
Jan-16-26 09:08AM	Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? (Zacks)
Jan-15-26 09:14AM	KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? (Zacks) -6.54%
Jan-13-26 08:08AM	JPM26: Sarepta CEO touts avalanche of Elevidys data amid 2025 safety woes (Pharmaceutical Technology)
Jan-12-26 04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily) -11.29%
12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga)
11:58AM	Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues (Business Wire)
Jan-05-26 08:30AM	Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-25 05:20PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-18-25 01:13PM	Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory (Insider Monkey)
Dec-11-25 07:00AM	Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027 (Business Wire)
Dec-03-25 11:30AM	Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report? (Zacks) +6.69%
Dec-02-25 08:00AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
Nov-25-25 02:17PM	Trump Media Stock and 11 More Tax-Loss Victims to Avoid Until 2026 (Barrons.com)
01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)
12:07PM	Trump Media and 11 More Stocks to Avoid Until 2026 (Barrons.com)
08:57AM	Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne (Business Wire)
Nov-24-25 07:30AM	Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics (Business Wire) +6.90%
Nov-17-25 09:32AM	FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings (Zacks) -6.75%
Nov-15-25 09:35AM	2 Beaten-Down Stocks to Avoid Right Now (Motley Fool)
Nov-14-25 03:14PM	FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths (Associated Press Finance) +5.56%
02:54PM	Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information (Business Wire)
Nov-06-25 05:43AM	Sarepta (SRPT) Soars 15% on Bullish Rating (Insider Monkey) -5.52%
Nov-05-25 10:21AM	Mizuho upgrades Sarepta on confidence in Elevidys uptake (Investing.com) +15.25%
03:31AM	Sarepta Stock Tumbles 34% After Earnings Report. Why Shares Crashed. (Barrons.com)
Nov-04-25 04:51PM	These Stocks Moved the Most Today: Palantir, Uber, Sarepta, Tesla, Norwegian Cruise Line, Hertz, AMD, and More (Barrons.com) -33.74%
04:14PM	Sarepta Loses A Third Of Its Value On Failed Tests, Gene Therapy Outlook (Investor's Business Daily)
02:39PM	These Stocks Are Moving the Most Today: Palantir, Uber, Sarepta, Tesla, Norwegian Cruise Line, Hertz, AMD, and More (Barrons.com)
01:46PM	SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure (Zacks)
11:54AM	Top Stock Movers Now: Palantir, Sarepta Therapeutics, Denny's, and More (Investopedia)
11:11AM	Sarepta Therapeutics Stock Tumbles After Trial Data (Schaeffer's Research)
10:59AM	Pfizer & Novo boost Metsera bids, Hertz stock skyrockets (Yahoo Finance Video)
10:14AM	Sarepta Loses Almost A Third Of Its Value On Failed Tests, Gene Therapy Outlook (Investor's Business Daily)
09:58AM	Sarepta Stock Tumbles 35% After Earnings Report. Why Shares Are Crashing. (Barrons.com)
09:39AM	Stocks to Watch Tuesday: Palantir, Sarepta, Tesla (The Wall Street Journal)
09:30AM	Sarepta Therapeutics (SRPT) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:05AM	Sarepta Earnings Beat Expectations. Why the Stock Is Down 40%. (Barrons.com)
07:39AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:13AM	Two of Sareptas DMD drugs fail to meet primary endpoint in confirmatory trial (Clinical Trials Arena)
06:20AM	Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking. (Barrons.com)
05:57AM	Palantir stock slides after earnings, and other early market movers (MarketWatch)
05:31AM	These Stocks Are Moving the Most Today: Palantir, Sarepta, Amazon, AMD, Pfizer, and More (Barrons.com)
04:00AM	Sarepta Duchenne drugs come up short in confirmatory test (BioPharma Dive)
12:00AM	Sarepta Therapeutics Inc (SRPT) Q3 2025 Earnings Call Highlights: Resilient Revenue Amidst ... (GuruFocus.com)
Nov-03-25 06:26PM	Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success (MarketWatch)
05:20PM	Sarepta Therapeutics (SRPT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:23PM	Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory Tests (Investor's Business Daily)
04:16PM	Sarepta Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE (Business Wire)
Oct-28-25 11:44AM	Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-27-25 04:05PM	Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results (Business Wire)
Oct-21-25 06:46AM	Tradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF (PR Newswire)
Oct-03-25 02:14PM	Sarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial Results (Insider Monkey)
08:30AM	Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress (Business Wire)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Estepan Ian Michael	Chief Operating Officer	Feb 26 '26	Option Exercise	13.71	7,450	102,140	200,750	Mar 02 08:00 AM
Nicaise Claude	Director	Jan 29 '26	Option Exercise	13.71	10,500	143,955	38,312	Jan 29 08:05 PM
BEHRENS M KATHLEEN	Director	Jan 27 '26	Option Exercise	13.71	10,500	143,955	203,976	Jan 29 08:04 PM
Estepan Ian Michael	Chief Operating Officer	Dec 16 '25	Sale	22.31	13,187	294,202	193,300	Dec 18 08:05 PM
IAN M ESTEPAN	Officer	Dec 16 '25	Proposed Sale	22.31	13,187	294,145		Dec 16 05:05 PM
Sarepta Therapeutics, Inc.	Shareholder	Aug 13 '25	Proposed Sale	19.99	9,265,312	185,213,587		Aug 13 08:55 PM
Barry Richard	Director	May 16 '25	Option Exercise	32.63	12,350	402,981	2,966,667	May 19 07:32 AM
Barry Richard	Director	May 13 '25	Option Exercise	19.23	20,246	389,359	2,954,317	May 15 07:00 AM
Nicaise Claude	Director	Mar 12 '25	Option Exercise	25.18	9,746	245,404	30,303	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Sale	99.64	2,491	248,203	27,812	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Proposed Sale	99.65	2,491	248,226		Mar 12 05:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRPT

Sarepta Therapeutics Inc

Upgrade your FINVIZ experience